Allergan PLC’s management team survived a shareholder vote driven by activist investors on 1 May, but chairman and CEO Brent Saunders’ statement that the message has been received was followed with virtually no specifics on how the firm’s business strategy will change.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?